Posted in | News | Chemistry | Petrochemicals

New Investment Helps Siluria Technologies to Optimize Natural Gas-to-Materials Platform

Siluria Technologies, the first company with technology for direct, cost-effective conversion of natural gas into chemicals, materials, and fuels, announced the close of its Series A round of funding.

The investment allows the company to optimize its groundbreaking natural-gas-to-materials platform to meet the performance levels required for commercialization. Its technology to create materials from natural gas will first target the $160 billion annual market for ethylene, the world’s largest commodity chemical.

Siluria’s investors include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and a strategic investment from Presidio Ventures, the venture arm of global trading and operating firm Sumitomo Corporation. The total raised in the round comes to $13.3 million.

In tandem with this announcement, the company speaks today at Chemical Engineering magazine’s landmark event in Houston, ChemInnovations. Alex Tkachenko, president of Siluria, will present “A Cost-Advantaged Route for Converting Natural Gas to Chemicals” as part of a session dedicated to alternative chemical pathways from 3:45 to 4:35 p.m.

“With the right technology, natural gas becomes an essential partner to petroleum-based methods for materials manufacturing,” said Dr. Alex Tkachenko, president of Siluria. “This new funding will help Siluria drive cost and carbon out of the manufacturing supply chain while creating significant new market outlets for natural gas providers.”

In place of resource-intensive processes based on petroleum, the Siluria platform offers a more cost-effective process that is directly compatible with the same industrial chemical manufacturing equipment used today. This breakthrough is made possible by Siluria’s novel synthetic technology, which produces inorganic materials in the same way nature makes them: by growing metals and metal oxide crystals on a biological template. The technology offers unique ways to manipulate catalyst surfaces, thus improving catalyst performance in structure-sensitive reactions, such as selective oxidations of light alkanes to olefins and oxygenates. This enables Siluria to optimize a chemical manufacturing process which many have tried to crack: methane activation.

“Siluria is pursuing the greatest challenge of efficient manufacturing – the ability to produce chemicals and fuels from natural gas, a cheaper, more abundant resource than oil,” said Sam Weinberger, advisor to Siluria and former Business Team Leader of ExxonMobil’s North American ethylene business. “By working within existing infrastructure, we can drive tens of billions of dollars in savings and a lower carbon way to produce the baby bottles, LCDs, housing materials and medical devices that enable modern life.”

Natural gas is the most abundant domestic resource in the United States with near zero import requirements. Siluria’s ethylene process leverages natural gas as a primary feedstock at a 40-60 percent lower price point compared to petroleum1. This innovative use of methane for chemical manufacturing presents significant new market possibilities for natural gas providers beyond electricity.

As Siluria optimizes its platform, the company will evaluate demonstration-scale partnerships with chemical manufacturers seeking greater supply chain flexibility and stability; natural gas providers seeking to increase their asset value; and plastic manufactures seeking to reduce the carbon footprint of their products across the supply chain from the first molecule to the store shelf.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.